Latest Private Placement News

Benz Mining Corp reported a CAD 3.58 million net loss for Q1 2025, driven by ramped-up exploration at its newly acquired Western Australian gold projects. The company bolstered its cash position with a CAD 27 million private placement post-period, aiming to fuel further resource growth.

Light & Wonder, Inc. has announced a proposed $1 billion private offering of senior unsecured notes due 2033, aiming to refinance existing debt and support corporate initiatives.

Resouro Strategic Metals updates the timing for its non-brokered private placement, aiming to close in the week of 15 September 2025. The funds will accelerate engineering work for the Tiros Titanium-Rare Earths Project’s Preliminary Economic Assessment.

Helix Resources has successfully raised close to $2 million through an oversubscribed rights issue and a follow-on placement, positioning the company to accelerate drilling and resource estimation at its White Hills and Gold Basin projects.

Kincora Copper has closed a fully subscribed $4 million private placement, positioning itself to advance drilling at its Condobolin project and expand its exploration portfolio.

PlaySide Studios has completed a $1.825 million Share Purchase Plan, adding to a recent $6.47 million private placement, to strengthen its balance sheet and support marketing efforts for upcoming game releases.

Orica Limited reports robust earnings growth across all segments for FY2025, underpinned by successful gas supply deals, digital expansion, and progress in hydrogen funding despite ongoing litigation costs.

Recce Pharmaceuticals reported a 21% increase in net loss to $21.4 million for FY2025, driven by intensified R&D spending. The company secured key regulatory approvals for Phase 3 trials of its lead anti-infective gel and bolstered its financial position with significant capital raises and grants.

Dotz Nano Limited reported a reduced half-year loss and significant progress in its Direct Air Capture technology, while navigating funding uncertainties with key investors.

Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.

Beonic Ltd reported a significantly reduced net loss of $3.17 million for FY2025, alongside improved margins and EBITDA profitability, underpinned by a major North African airport contract and a $4.18 million convertible note raise to accelerate growth.

SportsHero Limited reported a 189% revenue increase to AU$37,666 for FY25, driven by strategic partnerships across Southeast Asia, despite a continuing loss of nearly AU$2 million. The company secured major telco collaborations and expanded its gaming product footprint in Indonesia and the Philippines.